Virus Or Component Thereof Patents (Class 424/204.1)
Reassortant or deletion mutant virus (Class 424/205.1)
Retroviridae (e.g., feline leukemia virus, bovine leukemia virus, avian leukosis virus, equine infectious anemia virus, rous sarcoma virus, htlv-i, etc.) (Class 424/207.1)
Orthomyxoviridae (e.g., influenza virus, fowl plague virus, etc.) (Class 424/209.1)
Paramyxoviridae (e.g., parainfluenza virus, respiratory syncytial virus, rinderpest virus, sendai virus, canine tracheobronchitis virus, turkey rhinotracheitis virus, etc.) (Class 424/211.1)
Reoviridae (e.g., rotavirus, reovirus, orbivirus, avian proventriculitis virus, bluetongue virus, colorado tick fever virus, etc.) (Class 424/215.1)
Calciviridae or picornaviridae, except hepatitis a virus (e.g., foot-and- mouth disease virus (fmdv), coxsackievirus, echovirus, avian encephalomyelitis virus, mengovirus, etc.) (Class 424/216.1)
Togaviridae or flaviviridae, except hepatitis c virus (e.g., yellow fever virus, bovine viral diarrhea virus, dengue virus, equine viral arteritis virus, equine encephalitis virus, japanese b encephalitis virus, sindbis virus, flavivirus, etc.) (Class 424/218.1)
Coronaviridae (e.g., neonatal calf diarrhea virus, feline infectious peritonitis virus, canine coronavirus, etc.) (Class 424/221.1)
Rhabdoviridae (e.g., rabies virus, vesicular stomatitis virus, etc.) (Class 424/224.1)
Hepatitis virus (e.g., infectious canine hepatitis virus, duck hepatitis virus, mouse hepatitis virus, etc.) (Class 424/225.1)
Herpetoviridae (e.g., herpesvirus, mareks disease virus, laryngotracheitis virus, infectious bovine rhinotracheitis virus (ibr), infectious pustular vulvovaginitis virus, bovine herpes virus type 1, aujeszkys disease virus, feline rhinotracheitis virus, feline herpes virus, etc.) (Class 424/229.1)
Poxviridae (e.g., smallpox virus, avian pox virus, fowlpox virus, rabbit myxoma virus, vaccinia virus, etc.) (Class 424/232.1)
Adenoviridae, adeno-like virus, or parvoviridae (e.g., adenovirus, canine parvovirus, mink enteritis virus, hemorrhagic enteritis virus, feline panleukopenia virus, egg drop syndrome virus, etc.) (Class 424/233.1)
  • Controlled-release immunogenic formulations to modulate immune response
    Patent number: 8173104
    Abstract: Single-dose controlled-release immunogenic formulations, such as vaccines, based on bioerodible polyanhydride copolymer or homopolymer microparticles for the control of immune response mechanisms are provided. The copolymer or homopolymer microparticles degrade by surface-erosion from in vivo hydrolysis of anhydride linkages at the surface of the microparticle, which results in controlled release of immunogen(s) to a patient.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: May 8, 2012
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Matthew J. Kipper, Balaji Narasimhan, Jennifer H. Wilson, Michael J. Wannemuehler
  • Polycistronic HIV vector constructs
    Patent number: 8173137
    Abstract: The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: May 8, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Jan Zur Megede, Susan W. Barnett
  • Acyl pseudodipeptides which carry a functionalized auxiliary arm
    Patent number: 8173133
    Abstract: The present invention is directed in particular to dipeptide-like compounds derived from functionally substituted amino acids, having fatty acid chains bound thereto through amidification of the amine functional groups of said dipeptide-like compounds, one end portion of which bears an accessory functional side chain spacer, with the other end portion being an acid group either in neutral or charged state. Compounds of the present invention have immunomodulating properties like adjuvants, In addition, compounds of the invention can be grafted on a given antigen in order to modulate or tune the immune response or can be equally grafted on a pharmaceutical carrier to enhance the therapeutic effect or targeting thereof. Accordingly, compounds of the invention find use in human and veterinary medicine both as immunogens and diagnostic tools.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: May 8, 2012
    Assignee: OM Pharma
    Inventors: Jacques Bauer, Olivier Martin, Sylvain Rodriguez
  • Imidazoquinoxaline compounds as immunomodulators
    Patent number: 8173657
    Abstract: The invention provides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other agent(s).
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: May 8, 2012
    Assignee: Novartis AG
    Inventors: James Sutton, Feng Xu, Nicholas Valiante, Jiong Lan
  • VIRUS-LIKE PARTICLES OF CAPSID PROTEINS FROM HUMAN PAPILLOMAVIRUS TYPE 16/58/18/6/11 AND THE METHOD FOR PREPARATION AND THE USES THEREOF
    Publication number: 20120107350
    Abstract: Five optimized genes of capsid L1 protein from human papillomavirus type 16, 58, 18, 6 and 11, which are modified by using insect's preferred codons and so on. Method for modifying those genes to express more highly in insect cells. Virus-like particle's vaccine compositions comprising HPV L1 proteins or their functional relatives produced by using those modified genes. Those optimized genes of L1 can be used to produce HPV 16 VLP, HPV 58VLP, HPV 18VLP, HPV 6 VLP, HPV 11VLP in insect cells. Yields of virus-like particles derived from those optimized HPV L1 genes are high. Mixed multivalent vaccines comprising above optimized HPV L1 genes can be used to prevent and treat multiple HPV infection and diseases related with it.
    Type: Application
    Filed: September 18, 2007
    Publication date: May 3, 2012
    Inventors: Xuemei Xu, Ting Zhang, Yufei Xu, Dongsheng Fan
  • COMPOSITION
    Publication number: 20120107353
    Abstract: The invention relates to a composition comprising at least one ISCOM complex and at least one internal antigen which is not a surface antigen and not in the form of a part of a whole micro-organism. The internal antigen may be a nucleoprotein or presented as a member of the group of components obtained after disintegrating a micro-organism. The ISCOM complex may be an ISCOM or ISCOM matrix complex. The composition may also comprise non internal antigens. The invention also elates to the composition for use as an immune stimulating medicine or vaccine, especially for use in eliciting T cell respond including CTL respond. The invention also relate to a composition comprising at least one ISCOM complex for use as an immune stimulating or immune modulating medicine or vaccine for the stimulation of dendritic ceils in elderly.
    Type: Application
    Filed: July 9, 2010
    Publication date: May 3, 2012
    Applicant: ISCONOVA AB
    Inventors: Bror Morein, Karin Lövgren Bengtsson
  • LYMPH NODE-TARGETING NANOPARTICLES
    Publication number: 20120107268
    Abstract: Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1?, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in the presence of at least one cytokine to form a third composition. Further provided are methods of modulating an immune response comprising co-administering to a subject an antigen or vaccine with nanoparticles comprising heparin, chitosan, and at least one cytokine.
    Type: Application
    Filed: October 4, 2011
    Publication date: May 3, 2012
    Inventors: Soman Abraham, Kam Leong, Herman Staats, Ashley St. John
  • VIRAL VACCINE AND PROCESS FOR PREPARING THE SAME
    Publication number: 20120107354
    Abstract: The present invention provides a vaccine against a viral infection. The exemplary vaccine comprises a viral antigen of a vaccine strain of a virus; wherein the viral antigen is derived from a virus preparation of the vaccine strain of the virus; wherein the virus preparation of the vaccine strain of the virus contains a subpopulation of infectious viral particles, and the subpopulation of infectious viral particles is represented as a proportion over the total viral particles or total viral antigens of the virus preparation; and wherein the proportion of the subpopulation of infectious viral particles over the total viral particles or total viral antigens of the virus preparation is over a predefined threshold; so that the vaccine provides at least partial inter-subtypic or intra-subtypic cross immune response against different strains of the virus than the vaccine strain.
    Type: Application
    Filed: October 22, 2011
    Publication date: May 3, 2012
    Inventor: GEORGE DACAI LIU
  • METHOD OF RAPIDLY PRODUCING IMPROVED VACCINES FOR ANIMALS
    Publication number: 20120107355
    Abstract: A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal.
    Type: Application
    Filed: October 19, 2011
    Publication date: May 3, 2012
    Applicant: HARRISVACCINES, INC.
    Inventors: Delbert Linn Harris, Matthew Erdman, Kurt Iver Kamrud, Jonathan Smith, John Dustin Loy, Lyric Colleen Bartholomay, Ed Scura
  • LIPOPOLYSACCHARIDE OF OCHROBACTRUM INTERMEDIUM AND THEIR USE AS IMMUNOSTIMULANT OF MAMMALIANS
    Publication number: 20120107352
    Abstract: The present invention relates to the isolation, purification and characterization of the Lipopolysaccharide (LPS) from Ochrobactrum intermedium strain LMG3306, and their use as immunostimulant of mammalians, the process for the preparation of a pharmaceutical compound for the treatment and/or prevention of the sepsis and adjuvant for a vaccine in immunosupressed animals and against Leishmania.
    Type: Application
    Filed: December 31, 2009
    Publication date: May 3, 2012
    Inventors: Juan Ignacio Ovejero Guisasola, Manuel Fresno Escudero
  • MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS
    Publication number: 20120107348
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.
    Type: Application
    Filed: January 9, 2012
    Publication date: May 3, 2012
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
  • In Ovo Vaccination of Campylobacter in Avian Species
    Publication number: 20120107351
    Abstract: The present invention provides a method of inducing an immune response against Campylobacter in an avian species, especially a domesticated avian species such as chicken, turkey, duck, goose and quail, by administering, in ovo, live cells of Campylobacter.
    Type: Application
    Filed: January 5, 2012
    Publication date: May 3, 2012
    Applicant: Pfizer Inc.
    Inventors: Tonia Sue AGIN, Everett L. Rosey, Frederick H. Weber
  • Enterovirus type 71 protein and method for production
    Patent number: 8168192
    Abstract: The invention provides a new type of a capsid protein VP1 of human enterovirus 71, named as MEL701-VP1 and functional/structural variants thereof, which is used for protection against enterovirus. The transgenic animal producing the protein, the composition comprising the protein and the method for production thereof are also provided.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: May 1, 2012
    Assignee: National Chung Hsing University
    Inventors: Chuan-Mu Chen, Hsiao-Ling Chen
  • Compositions And Methods For Treatment Of Microbial Infections
    Publication number: 20120100178
    Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
    Type: Application
    Filed: October 24, 2011
    Publication date: April 26, 2012
    Inventors: Jiri Pillich, John C. Balcarek
  • USE OF MICRORNAS TO CONTROL VIRUS HELPER NUCLEIC ACIDS
    Publication number: 20120100179
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Application
    Filed: November 25, 2009
    Publication date: April 26, 2012
    Applicant: ALPHAVAX, INC.
    Inventors: Vernon McNeil Coffield, Kurt I. Kamrud, Jonathan F. Smith
  • METHODS FOR PROLIFERATION OF ANTIGEN-SPECIFIC T CELLS
    Publication number: 20120100180
    Abstract: Methods for expansion of antigen-specific T cells are provided. Said methods include following steps: generating antigen-specific T cells by stimulation of T cells with antigen A; introducing genes encoding immune recognition molecule specific to major histocompatibility complex (MHC) molecule bound with a peptide derived from antigen B into the antigen A specific T cell to produce bi-specific T cells recognizing both target cells expressing antigen A peptide associated MHC and target cells expressing antigen B peptide associated MHC; stimulating the bi-specific T cells by antigen A for expansion of the bi-specific T cells in vitro or in vivo. Methods of the present invention can be applied to expand various of T cells with specific to cancer cells with tumor antigen peptide loaded MHC molecules for adoptive therapy against unmet medical need such as tumors etc.
    Type: Application
    Filed: April 3, 2009
    Publication date: April 26, 2012
    Applicant: Institute of Microbiology,Chinese Academy of Sciences
    Inventors: Bin Gao, Jie Ding
  • RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF
    Publication number: 20120093855
    Abstract: The present invention relates to the field of isolation of enveloped virus-based virus-like particles (VLPs) free of infectious agents. In preferred examples, the field includes methods of inactivation of infectious agents that do not adversely affect the immunogenicity of the enveloped virus-based VLPs. In certain embodiments, the enveloped virus-based VLPs are produced in insect cell based expression systems.
    Type: Application
    Filed: November 18, 2009
    Publication date: April 19, 2012
    Applicant: LIGOCYTE PHARMACEUTICALS, INC.
    Inventor: Joel R. Haynes
  • METHODS FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE RESPONSE AND INFLAMMATION
    Publication number: 20120093856
    Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.
    Type: Application
    Filed: December 2, 2011
    Publication date: April 19, 2012
    Inventors: Michail V. Sitkovsky, Akio Ohta
  • CDNA corresponding to the antigenome of nonsegmented negative strand RNA viruses, and process for the production of such viruses encoding additional antigenically active proteins
    Patent number: 8158416
    Abstract: The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a mode for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: April 17, 2012
    Assignee: Crucell Switzerland AG
    Inventors: Martin A. Billeter, Pius Spielhofer, Karin Kalin, Frank Radecke, Henriette Schneider
  • Recombinant MVA virus
    Patent number: 8153138
    Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: April 10, 2012
    Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH
    Inventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
  • Flavivirus fusion inhibitors
    Patent number: 8153360
    Abstract: The present invention provides an isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:36, as well as derivatives thereof comprising various N-terminal and C-terminal chemical moieties, substituted analogs thereof, and fragments thereof. The peptides of the invention are useful for treating and preventing a Flavivirus invention. Pharmaceutical compositions comprising the peptides, and methods of treating or preventing Flavivirus infections, are also provided.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: April 10, 2012
    Assignees: The Administrators of the Tulane Educational Fund, The Rockefeller University
    Inventors: Robert F. Garry, Srikanta Dash, David H. Coy, Jane A. McKeating
  • Oncolytic virus
    Patent number: 8147822
    Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR?/?, STAT1?/? or both PKR?/? and STAT1?/?. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: April 3, 2012
    Assignee: Wellstat Biologics Corporation
    Inventors: John C. Bell, Nahum Sonenberg, David F. Stojdl, Earl G. Brown, Harold L. Atkins, Ricardo M. Marius, Brian D. Lichty, Shane B. Knowles
  • Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions
    Patent number: 8147845
    Abstract: Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: April 3, 2012
    Assignee: Oncolytics Biotech Inc.
    Inventors: Donald Morris, Bradley G. Thompson, Matthew C. Coffey
  • Compositions And Methods For Treating of Microbial Infections
    Publication number: 20120076819
    Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
    Type: Application
    Filed: August 30, 2011
    Publication date: March 29, 2012
    Applicant: Immunology Labs, Inc.
    Inventors: Jiri Pillich, John Balcarek
  • PLASMIDS WITH IMMUNOLOGICAL ACTION
    Publication number: 20120076807
    Abstract: Recombinant plasmids usable for the transfection of eukaryotic and prokaryotic cells are described; such plasmids have a length comprised between 7 and 12 kbases and comprise a sequence encoding the heavy chain of an immunoglobulin; in particular, they may be used: in a process of transfection of prokaryotic or eukaryotic cells (ex vivo) which can be inoculated into higher organisms in order to induce a prophylactic or therapeutic immune response; in a protocol of direct inoculation (in vivo) in higher organisms in genic immunization methodologies with the aim of evoking prophylactic or therapeutic immune responses.
    Type: Application
    Filed: May 26, 2011
    Publication date: March 29, 2012
    Applicant: International Investment and Patents S.A.
    Inventor: Mara Gerloni
  • Hepatitis C Virus Inhibitors
    Publication number: 20120076755
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W??(I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: October 4, 2011
    Publication date: March 29, 2012
    Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Hui Cao, Yat Sun Or
  • NOVEL BENZIMIDAZOLE DERIVATIVES
    Publication number: 20120076756
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: October 4, 2011
    Publication date: March 29, 2012
    Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Yat Sun Or
  • Norovirus and Sapovirus antigens
    Patent number: 8142793
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: March 27, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
  • Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
    Patent number: 8137672
    Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: March 20, 2012
    Assignee: The Regents of the University of Colorado
    Inventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
  • Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer
    Patent number: 8137674
    Abstract: The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: March 20, 2012
    Assignees: Postech Foundation, Genexine Co., Ltd.
    Inventors: Young Chul Sung, Hyun Tak Jin, Sang Hwan Seo, Sang Hoon Park, Je-In Youn
  • ENHANCED IMMUNE RESPONSE IN AVIAN SPECIES
    Publication number: 20120064151
    Abstract: The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the avian species. The method is particularly effective for protecting a member of the avian species from infectious disease and treating animals inflicted with infectious disease.
    Type: Application
    Filed: May 7, 2010
    Publication date: March 15, 2012
    Applicant: Bayer Animal Health GmbH
    Inventor: Albert Abraham
  • RECOMBINANT VIRUS-LIKE PARTICLES ENCODED BY MULTI-GENE VECTOR
    Publication number: 20120064115
    Abstract: The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface.
    Type: Application
    Filed: April 30, 2010
    Publication date: March 15, 2012
    Inventors: Corinne John, Christian Schaub, Sabine Wellnitz
  • LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
    Publication number: 20120058144
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures XIV or XVII.
    Type: Application
    Filed: November 10, 2009
    Publication date: March 8, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Narayanannair, Marco A. Ciufolini
  • STABLE, SPRAY DRYED, IMMUNOGENIC, VIRAL COMPOSITIONS
    Publication number: 20120058162
    Abstract: Viruses, and particularly genetically engineered, replication deficient viruses such as adenoviruses, poxviruses, MVA viruses, and baculoviruses which encode one or more antigens of interest, such as TB, malarial, and HIV antigens, are spray dried with a mannitol-cyclodextrin-trehalose-dextran (MCTD) to form a powder where the viability of the viruses are maintained at a suitable level for mass vaccinations after spray drying, and where the viability of the viruses are maintained at suitable level over a period of storage time, even in the presence of humidity.
    Type: Application
    Filed: May 20, 2010
    Publication date: March 8, 2012
    Inventors: Tom Han Jin, Eric I-Fu Tsao
  • 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase
    Publication number: 20120058079
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Application
    Filed: November 11, 2011
    Publication date: March 8, 2012
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
  • METHOD FOR PRODUCING VIRUS FROM CELL CULTURE INVOLVING HOMOGENIZATION
    Publication number: 20120058145
    Abstract: A method of purifying a virus, or a viral antigen thereof, from a culture of infected cells comprising at least the steps of: (a) collecting the virus-containing cell culture medium, and (b) purifying the virus, wherein at least one homogenization step is implemented during the purification to obtain a virus homogenate.
    Type: Application
    Filed: May 6, 2010
    Publication date: March 8, 2012
    Inventors: Bruno Rene Andre, Benoit Paul Suzanne Champluvier
  • N protein mutants of porcine reproductive and respiratory syndrome virus
    Patent number: 8128937
    Abstract: The present invention provides a genetically modified PRRS virus, methods to make it and related polypeptides, polynucleotides and various components. Vaccines comprising the genetically modified virus and polynucleotides are also provided.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: March 6, 2012
    Assignee: Pfizer Inc.
    Inventors: Dongwan Yoo, Changhee Lee, Jay Gregory Calvert, Siao-Kun Welch
  • VACCINES AGAINST TULAREMIA
    Publication number: 20120052085
    Abstract: The disclosure relates generally to an antigenic composition useful for immunization against tularemia. The disclosure is a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia.
    Type: Application
    Filed: May 3, 2010
    Publication date: March 1, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Marcus A. Horwitz, Qingmei Jia, Bai-Yu L. Clemens
  • VACCINES FOR HUMAN PAPILLOMA VIRUS AND METHODS FOR USING THE SAME
    Publication number: 20120053509
    Abstract: Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV 6, HPV 11, HPV 33 and HPV58 E6 and E7. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.
    Type: Application
    Filed: October 12, 2011
    Publication date: March 1, 2012
    Inventors: David B. WEINER, Jian YAN
  • Influenza antigens, vaccine compositions, and related methods
    Patent number: 8124103
    Abstract: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: February 28, 2012
    Assignee: Fraunhofer USA, Inc
    Inventors: Vidadi Yusibov, Vadim Mett, Konstantin Musiychuck
  • Norovirus and sapovirus antigens
    Patent number: 8124104
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: February 28, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
  • Inactivating pathogens with oxidizing agents for vaccine production
    Patent number: 8124397
    Abstract: The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided.
    Type: Grant
    Filed: August 7, 2006
    Date of Patent: February 28, 2012
    Assignee: Oregon Health & Science University
    Inventors: Mark K. Slifka, Shirley V. Carter, Erika Hammarlund, Paul Yoshihara
  • Inactivated nodavirus vaccine
    Patent number: 8124100
    Abstract: A vaccine against nodavirus infection in fish can be produced by inactivating the virus using an aziridine compound. This vaccine can be used to prevent Viral Nervous Necrosis (VNN) in a variety of fish species.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: February 28, 2012
    Assignee: Novartis AG
    Inventors: Nuno Dos Santos, Jacqueline Ireland, Andrew Cartner Barnes, Michael Horne
  • Dry Powder Formulations, Vaccines and Methods
    Publication number: 20120045479
    Abstract: Respirable dry powder formulations comprise myo-inositol and leucine. Dry powder human papillomavirus (HPV) vaccine formulations comprise a least one HPV capsid protein and a carrier comprising myo-inositol and leucine. Methods of administering an HPV vaccine to an individual comprise inhalation administration to the individual of a dry powder HPV vaccine formulation comprising a least one HPV capsid protein and a carrier comprising myo-inositol and leucine.
    Type: Application
    Filed: October 15, 2009
    Publication date: February 23, 2012
    Inventors: Robert E. Sievers, Robert L. Garcea, Stephen P. Cape
  • Multivalent PCV2 immunogenic compositions and methods of producing such compositions
    Patent number: 8119143
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: February 21, 2012
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
  • HIV-1 Clade A consensus sequences, antigens, and transgenes
    Patent number: 8119144
    Abstract: The present invention relates to consensus nucleotide and protein sequences for HIV-1 Clade A antigens, and to nucleotide and protein sequences for Clade A antigens from circulating HIV-1 field isolates wherein the antigen sequences are closely related to the these consensus sequences. In a preferred embodiment, the present invention relates to HIV-1 Clade A transgenes that are derived from such sequences, and that encode either HIV-1 Clade A Gag, Pol (RT and Int), and Nef (referred to as “GRIN”), HIV-1 Clade A Gag, RT, and Nef (referred to as (“GRN”), or HIV-1 Clade A Env. The invention also relates to vectors containing such transgenes, including in preferred embodiment, adenovirus vectors containing such transgenes.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: February 21, 2012
    Assignee: International AIDS Vaccine Initiative
    Inventors: Kalpana Gupta, Nicholas Jackson
  • Methods for producing norovirus VLPS
    Patent number: 8119145
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: February 21, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
  • COMPOSITIONS AND METHODS FOR VACCINE AND VIRUS PRODUCTION
    Publication number: 20120039939
    Abstract: The present invention features methods of producing immunogenic compositions and viruses, methods of treating and preventing viral infection, and methods of producing an immune response using cells that express a polypeptide selected from the group consisting of: cdk13, siat7e, Iama4, cox15, egr1, gas6, map3k9, and gap43, and a virus.
    Type: Application
    Filed: April 10, 2009
    Publication date: February 16, 2012
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Joseph Shiloach, Michael Betenbaugh, Pratik Jaluria, Chia Chu
  • MICROPARTICULATED VACCINES FOR THE ORAL OR NASAL VACCINATION AND BOOSTERING OF ANIMALS INCLUDING FISH
    Publication number: 20120040010
    Abstract: The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.
    Type: Application
    Filed: March 26, 2010
    Publication date: February 16, 2012
    Inventors: Moti Harel, Brian Carpenter
  • Structural proteins of fish pancreatic disease virus and uses thereof
    Patent number: 8114409
    Abstract: The present invention relates to the structural proteins of the causative agent of Pancreatic Disease in fish, nucleotide sequences encoding said proteins, vaccines comprising said proteins or nucleotide sequences and diagnostic kits comprising said proteins or nucleotide sequences.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: February 14, 2012
    Assignee: Intervet Intenational B.V.
    Inventors: Jonathan Weston, Daniel Todd